Skip to main content
. 2017 Oct 5;24:3–7. doi: 10.1016/j.amsu.2017.09.018

Table 2.

Objectives and results.

Year Author Objectives Results
2008 Centeno CJ et al. Pre- and post-treatment subjective VAS pain scores, physical therapy assessments, and MRIs At 24 weeks post-injection, the patient had statistically significant cartilage and meniscus growth on MRI, as well as increased range of motion and decreased modified VAS pain scores.
2014 Jaewoo Pak et al. Pre- and post-treatment VAS walking index, Functional rating index, range of motion and MRI Three months after the treatment, the patient's symptoms improved. Repeated MRI showed almost complete disappearance of the torn meniscus.
2014 Vangsness CT Jr et al. Patients were randomized to one of three treatment groups:
Group A- Injection of 50 × 106 allogeneic MSC
Group B- 150 × 106 allogeneic MSC and the
Control group- sodium hyaluronate vehicle control.
Evaluate safety, meniscus regeneration, overall condition of the knee joint, and clinical outcomes at intervals through two years.		 No ectopic tissue formation or clinically important safety issues were identified. There was significantly increased meniscal volume (defined a priori as a 15% threshold) determined by quantitative MRI in 24% of patients in Group A and 6% in Group B at twelve months post meniscectomy (p = 0.022). No patients in the control group met the 15% threshold for increased meniscal volume. Patients with osteoarthritic changes who received mesenchymal stem cells experienced a significant reduction in pain compared with those who received the control, on the basis of VAS assessments.
2017 Whitehouse MR et al. Pre- and post-treatment IKDC and Tegner-Lysholm scores, range of motion and MRIs 3 out of the 5 patients had a successful outcome at 24 months showing improvements in all clinical scores over the first 12 months. Out of the 2 patients with failed implants, 1 had a tear at the implant site and the other had incomplete healing of the meniscus. These 2 patients showed no improvement in clinical scores between the 6–12 month period but had lower baseline Tegner-Lysholm scores compared to the other patients.